Search
Vancomycin is used to treat serious gram-positive infections in children; however, effective dosing information for those aged 3 months to 18 years is limited. We aimed to determine an optimized dosing strategy for this age group.
Vancomycin is first-line treatment for methicillin-resistant Staphylococcus aureus infections. However, despite guideline recommendations, there is no evidence that targeting vancomycin trough concentrations of ≥15 mg/L in children confers clinical benefit and is associated with vancomycin-associated nephrotoxicity.
Dr Laurence Cheung is doing everything he can to end the threat of childhood leukemia. His research has the potential to change countless lives, but he also has another important job – being a dad to three beautiful children.
Children at risk of potentially life-threatening Strep A infections no longer have to wait five days for timely treatment, thanks to a The Kids Research Institute Australia study conducted in the remote Kimberley region of Western Australia.
Resonance Health Ltd is pleased to announce that it has entered into a licence agreement with The Kids Research Institute Australia and the Erasmus University Medical Centre.
Kids born with Down syndrome are at high risk of an array of health problems. One of the lesser-known complications is their increased risk of childhood leukaemia.
The Kids Research Institute Australia and University of Western Australia physical activity researcher Hayley Christian has been named Young Tall Poppy Scientist of the Year at the 2020 WA Young Tall Poppy Science Awards.
CliniKids, the first stand-alone clinical service offered by The Kids Research Institute Australia, was launched in October 2019 and is already delivering benefits for families with children who are developing differently.
Vaccination to prevent infectious disease is one of the most successful public health interventions ever developed. And yet, variability in individual vaccine effectiveness suggests that a better mechanistic understanding of vaccine-induced immune responses could improve vaccine design and efficacy.
Genetic screening technologies to identify and validate macromolecular interactions (MMIs) essential for complex pathways remain an important unmet need for systems biology and therapeutics development. Here, we use a library of peptides from diverse prokaryal genomes to screen MMIs promoting the nuclear relocalization of Forkhead Box O3 (FOXO3a), a tumor suppressor more frequently inactivated by post-translational modification than mutation.